enow.com Web Search

  1. Ad

    related to: jak inhibitors brand name drugs

Search results

  1. Results from the WOW.Com Content Network
  2. Janus kinase inhibitor - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase_inhibitor

    A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

  3. Janus kinase 3 inhibitor - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase_3_inhibitor

    Janus kinase 3 inhibitors, also called JAK3 inhibitors, are a new class of immunomodulatory agents that inhibit Janus kinase 3. They are used for the treatment of autoimmune diseases . The Janus kinases are a family of four nonreceptor tyrosine-protein kinases, JAK1 , JAK2 , JAK3 , and TYK2 .

  4. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

  5. Tofacitinib - Wikipedia

    en.wikipedia.org/wiki/Tofacitinib

    Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis. [8] [9] [10] It is a janus kinase (JAK) inhibitor, [8] [9] discovered and developed by the National Institutes of ...

  6. Baricitinib - Wikipedia

    en.wikipedia.org/wiki/Baricitinib

    Baricitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits Janus kinase 1 with a half maximal inhibitory concentration (IC 50) of 5.9 nM and Janus kinase 2 with an IC 50 of 5.7 nM. Tyrosine kinase 2 , which belongs to the same enzyme family, is affected less (IC 50 = 53 nM), and Janus kinase 3 far less (IC 50 > 400 nM).

  7. Can JAK Inhibitors Challenge Biologics?

    www.aol.com/news/2013-02-20-can-jak-inhibitors...

    If JAK inhibitors can show similarly impressive results, gain approval, and make a splash, then these blockbuster biologics could have some real competition. While the future is promising that "if ...

  8. After FDA, European Agency Limits Use Of Certain JAK ... - AOL

    www.aol.com/news/fda-european-agency-limits...

    The European Medicine Agency's safety committee recommended that a group of JAK inhibitors for chronic inflammatory disorders be only used in certain at-risk patients if no alternatives are available.

  9. Filgotinib - Wikipedia

    en.wikipedia.org/wiki/Filgotinib

    Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively, similar to already marketed upadacitinib. [medical citation needed] Less selective JAK inhibitors (e.g. tofacitinib and baricitinib) are already being marketed.

  1. Ad

    related to: jak inhibitors brand name drugs